Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension

Main Category: Hypertension
Also Included In: Clinical Trials / Drug Trials
Article Date: 17 Jul 2006 - 23:00 PDT

Current ratings for:
'Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension'

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Takeda Pharmaceutical has announced that its investigational compound TAK-491 has entered into the Phase II clinical stage in the US and Europe.

An angiotensin receptor blocker (ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor hormone Angiotensin II.

The new compound is superior to the conventional ARB in that it demonstrates stronger anti-hypertension action, improves the insulin resistance, and decreases proteinuria.

TAK-491 is expected to support the expansion of the US diabetic franchise of Actos (generic name: pioglitazone HCI) into lifestyle-related diseases. Also, the new drug will help the company increase its presence in the European cardiovascular market along with Candesartan, another drug found by Takeda which treats hypertension.

By Aki Tsukioka, JCN Staff Writer

Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.

JCN

View drug information on ACTOS.


Article adapted by Medical News Today from original press release.
Visit our hypertension section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christopher Backing. "Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension." Medical News Today. MediLexicon, Intl., 17 Jul. 2006. Web.
26 May. 2012. <http://www.medicalnewstoday.com/releases/47246.php>
APA
Christopher Backing. (2006, July 17). "Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/47246.php.

Please note: If no author information is provided, the source is cited instead.


Add Your Opinion On This Article

'Takeda Pharmaceutical Initiates Phase II Clinical Test For Compound TAK-491 For Treatment Of Hypertension'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Hypertension

Most Popular Articles



Follow Our Hypertension News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Hypertension Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »